Furosemide Administration in Acute Heart Failure
For acute heart failure with congestion, start with an IV bolus of 20-40 mg furosemide given slowly over 1-2 minutes, but only if systolic blood pressure is ≥90 mmHg and the patient is not markedly hypovolemic. 1, 2
Initial Dosing Strategy
Dose Selection Based on Prior Diuretic Use
- Diuretic-naive patients or new-onset heart failure: Start with 20-40 mg IV bolus 1, 3
- Patients already on chronic oral diuretics: The initial IV dose must be at least equivalent to (or greater than) their home oral dose 1, 2, 4
- Severe volume overload with prior diuretic exposure: Higher initial doses may be required based on renal function and chronic diuretic history 1
Administration Technique
- Give the IV bolus slowly over 1-2 minutes to minimize ototoxicity risk 1, 3
- Place a bladder catheter immediately to monitor urinary output and rapidly assess treatment response 1, 2
- Assess patients frequently in the initial phase to follow urine output 1
Critical Pre-Administration Requirements
Absolute Contraindications - Do Not Give Furosemide If:
- Systolic blood pressure <90 mmHg without circulatory support 1, 2, 4
- Marked hypovolemia 1, 2, 4
- Severe hyponatremia 1, 2, 4
- Acidosis 1
- Anuria or dialysis-dependent renal failure 1, 2
Common Pitfall to Avoid
Never start furosemide in hypotensive patients expecting it to improve hemodynamics—it will worsen hypoperfusion and precipitate cardiogenic shock. 2, 4 If systolic blood pressure is <100 mmHg or >30 mmHg below baseline, patients require circulatory support with inotropes, vasopressors, or intra-aortic balloon counterpulsation before or concurrent with diuretic therapy. 2, 4
Dose Escalation and Continuous Infusion
When to Escalate
- If inadequate diuretic response after initial bolus, increase the dose according to renal function and chronic diuretic use history 1
- Continuous infusion may be considered after the initial starting dose in patients with evidence of volume overload 1
Continuous Infusion Protocol
- Start at 3 mg/hour, doubling the infusion rate hourly until adequate diuresis is achieved 2
- Maximum infusion rate: 24 mg/hour 2
- Alternative dosing: 5-10 mg/hour with maximum rate not exceeding 4 mg/min during administration 4, 3
Dose Limits
- Total furosemide dose should remain <100 mg in the first 6 hours 1
- Total dose should remain <240 mg during the first 24 hours 1
Evidence for Continuous vs. Intermittent Dosing
Research shows continuous infusion yields comparable urinary output with lower total doses and fewer fluctuations in urinary output compared to intermittent boluses. 5, 6 A study in congestive heart failure demonstrated that continuous infusion following a loading dose produced 12-26% greater diuresis and 11-33% greater natriuresis than intermittent administration. 6
Monitoring Requirements
Target Urine Output
Laboratory Monitoring
- Electrolytes (potassium, sodium): Check frequently, especially when doses exceed 80 mg/day 1, 4
- Renal function (creatinine, eGFR): Monitor within 6-24 hours after administration 2, 4
- Blood pressure: Monitor every 15-30 minutes in the first 2 hours after administration 2, 4
Stop Furosemide Immediately If:
- Severe hyponatremia develops 1, 4
- Progressive renal failure or acute kidney injury occurs 2, 4
- Marked hypotension develops 2, 4
- Hypovolemia and dehydration occur 1
Managing Diuretic Resistance
Combination Therapy Approach
When inadequate response occurs after reaching maximum infusion rates, add a second diuretic rather than exceeding furosemide dose limits. 1, 2
- Thiazides: Hydrochlorothiazide 25 mg PO 1, 4
- Aldosterone antagonists: Spironolactone or eplerenone 25-50 mg PO 1, 4
- Rationale: Combinations in low doses are often more effective with fewer side effects than higher doses of a single drug 1
Potential Adverse Effects
Electrolyte Disturbances
- Hypokalaemia, hyponatraemia, hyperuricaemia 1
Volume-Related Complications
- Hypovolaemia and dehydration—assess urine output frequently 1
- May increase hypotension following initiation of ACEI/ARB therapy 1
Neurohormonal Effects
- Neurohormonal activation 1
Ototoxicity
- Risk increases with rapid IV administration or very high doses 4, 3
- Administer slowly over 1-2 minutes to minimize risk 1, 3
Special Populations
Pediatric Patients
- Initial dose: 1 mg/kg IV given slowly under close medical supervision 3, 7
- May increase by 1 mg/kg not sooner than 2 hours after previous dose 3, 7
- Maximum dose: 6 mg/kg body weight 3, 7
- Premature infants: Maximum 1 mg/kg/day 3, 7